The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 31, 2017

Filed:

Feb. 07, 2012
Applicants:

Axel Hoffmann, Wehrheim, DE;

Heinrich Lannert, Schwetzingen, DE;

Klaus Brischwein, Munich, DE;

Frederic Christian Pipp, Gruendau, DE;

Juergen Reindl, Rossdorf, DE;

Karin Groll, Muehltal, DE;

Michael Zuehlsdorf, Darmstadt, DE;

Otmar Pfaff, Frankfurt am Main, DE;

Sabine Raab, Rosbach, DE;

Ulrike Dau, Darmstadt, DE;

Benoit Destenaves, Peron, FR;

Inventors:

Axel Hoffmann, Wehrheim, DE;

Heinrich Lannert, Schwetzingen, DE;

Klaus Brischwein, Munich, DE;

Frederic Christian Pipp, Gruendau, DE;

Juergen Reindl, Rossdorf, DE;

Karin Groll, Muehltal, DE;

Michael Zuehlsdorf, Darmstadt, DE;

Otmar Pfaff, Frankfurt am Main, DE;

Sabine Raab, Rosbach, DE;

Ulrike Dau, Darmstadt, DE;

Benoit Destenaves, Peron, FR;

Assignee:

Merck Patent GmbH, Darmstadt, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/2848 (2013.01); C07K 16/3069 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract

The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.


Find Patent Forward Citations

Loading…